Investor Relations

Corporate Profile

Based in South San Francisco, we are a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Kezar is translating its innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class immunoproteasome inhibitor, is currently in a Phase 1b trial, with a Phase 2 trial in lupus nephritis patients expected to initiate during the first half of 2019. Kezar is also poised to expand its development programs throughout 2019 with plans to initiate multiple Phase 2 trials of KZR-616, in up to four additional autoimmune indications, and to nominate an initial clinical candidate for the treatment of cancer from its protein secretion program.

Stock Quote

Donec sed odio dui. Cras justo odio, dapibus ac facilisis in, egestas eget quam.

More information is coming soon.

Stock Chart

Copyright West LLC. Minimum 15 minutes delayed.